// App-Quantinova.ai

754 : Targeting carbonic anhydrase IX in multiple pancreatic ductal adenocarcinoma models results in tumor growth inhibition and increased survival

Researchers

Presenter

  • Paul C. McDonald

Principal Investigators

  • Shawn C. Chafe

  • Marylou Vallejo

  • David Schaeffer

  • Don Yapp

  • Claudiu T. Supuran

  • Ben Stanger

  • Mac Parmar

  • Daniel Renouf

  • Shoukat Dedhar

Medical Centers

  • British Columbia Cancer Research Centre, Vancouber, British Columbia, Canada.

  • Vancouver General Hospital, Vancouver, BC, Canada

  • Universita degli Studi di Firenze, Italy.

  • University of Pennsylvania, Philadelphia, PA

  • SignalChem Lifesciences Corp, Richmond, British Columbia, Canada

  • BC Cancer Agency, Vancouver, British Columbia, Canada.

Locations

  • United States

  • Canada

  • Italy

Companies

  • SignalChem

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Pancreas ductal adenocarcinoma

  • Pancreatic cancer

  • Breast cancer

  • Solid malignancies

  • Microphthalmia, syndromic, 9

Biomarkers

  • p53

  • Carbonic anhydrase IX

  • KRAS proto-oncogene, GTPase

Drug/Treatment

  • Gemcitabine

  • SLC0111

Outcome

  • N/A

Study Design

  • Adaptive

Phase

  • I

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved